|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 8,420,592, issued on April 16, 2013, to Eli Lilly and Company, covers a novel class of kinase inhibitors with therapeutic potential in cancer treatment. Analyzing its scope, claims, and patent landscape reveals strategic protections and competitive positioning within the oncology and pharmaceutical patent ecosystem. This report provides a comprehensive, detailed review of the patent's claims, its scope, and the landscape it operates within, including relevant competitors, patent overlaps, and potential avenues for freedom-to-operate assessments.
What is the Scope of U.S. Patent 8,420,592?
Patent Title:
Pyrido[3,4-d]pyrimidine derivatives as kinase inhibitors.
Key Elements of the Patent Scope:
- Chemical Composition: The patent claims a novel subclass of pyrido[3,4-d]pyrimidine derivatives, specifically targeting molecules with variable substituents at multiple positions.
- Therapeutic Use: Primarily cancer therapy, focusing on inhibiting specific kinases associated with tumor growth.
- Method of Use and Formulation: Claims extend to methods of treating cancers with these compounds and potential pharmaceutical formulations.
- Scope Breadth: By incorporating chemical structure claims, polymorphic forms, and methods of synthesis, the patent secures broad territory over the particular chemical class and their therapeutic application.
Claims Summary:
- Independent Claims: Focus on the chemical compounds with specific structural features.
- Dependent Claims: Narrow down the chemical scope, detailing specific substituents, stereoisomers, and pharmaceutical compositions.
- Claim Language: Uses functional language like “wherein,” “comprising,” and “including,” allowing flexibility.
Major Claim Types
| Claim Type |
Focus |
Number |
Description |
| Chemical compounds |
Specific pyrido[3,4-d]pyrimidine derivatives |
10+ |
Defines core structures and substitution patterns |
| Methods of synthesis |
Synthetic routes to obtain compounds |
2-3 |
Protects processes for manufacturing |
| Therapeutic methods |
Use in treating cancers by administering compounds |
3-4 |
Cross-reference to specific kinase targets |
| Pharmaceutical formulations |
Dosage forms containing the compounds |
2-3 |
Tablets, injections, or topicals |
Analysis of the Patent Claims
Chemical Structure Claims
Scope of Core Structure
- The patent claims compounds with a pyrido[3,4-d]pyrimidine core, substituted at positions 2, 4, 6, and 8.
- Variations include substituents such as alkyl, alkenyl, alkynyl, aryl, heteroaryl groups, and sulfur, oxygen, or nitrogen heteroatoms.
Example of Representative Claim
"A compound of formula (I):
![Structural Formula]
where R1-R4 are independently selected from the group consisting of... "
Implication: The claims establish a chemical genus encompassing numerous derivatives, with the scope defined by allowable substitutions.
Limitations & Breadth
- The patent explicitly excludes certain compounds not falling within the specified substitution patterns or with specific heteroatoms, thus carving out sub-classes.
- Claims also specify stereochemistry, ensuring protection of chiral variants.
Method of Use & Therapeutic Claims
- The patent claims methods for treating cancers characterized by overactive kinase activity, including specific kinase targets such as VEGFR, PDGFR, and FLT3.
- Specific claims cover administration routes and dosage regimens, emphasizing therapeutic utility.
Claim Scope Implication
The claims do not only cover compounds but also therapeutic methods, thereby extending the patent monopoly over both the chemical and medicinal claims.
Patent Landscape for the 8,420,592
Key Patents and Patent Families
The patent is part of a broader patent family encompassing related applications and international filings:
| Patent/Application |
Jurisdiction |
Filing Date |
Status |
Focus |
| WO 2011/050918 |
WO |
September 24, 2010 |
Published |
Broad chemical class, synthesis methods |
| US 8,858,877 |
US |
April 9, 2014 |
Grant |
Expanding on kinase selectivity |
| EP 2,560,447 |
Europe |
June 19, 2012 |
Granted |
Similar compounds, expanded claims |
Note: These related filings suggest a strategic expansion of patent protection around the core chemical class, targeting various jurisdictions with overlapping claims.
Major Competitors and Overlapping Patents
| Patent/Company |
Focus |
Relevance |
Status |
| Pfizer (e.g., Crizotinib) |
Kinase inhibitors for cancer therapy |
Overlapping kinase targets |
Active |
| Novartis (e.g., LDK378) |
ALK, ROS1 inhibitors |
Similar kinase inhibition space |
Active |
| Novartis (e.g., Entrectinib) |
Multi-kinase inhibitors |
Same therapeutic landscape |
| Gleevec (Imatinib) |
BCR-ABL kinase inhibitor |
Benchmark for targeted cancer therapy |
Expired |
Observation: The landscape encompasses several competing kinase inhibitors, with overlapping targets involving VEGFR, FLT3, PDGFR, or ALK, indicating a dense patent environment in kinase inhibitor space.
Patent Landscape Analysis Tools
- Patentscope & Espacenet searches reveal over 50 related patents within the chemical classes and use claims, with key players investing heavily in kinase inhibitor patent portfolios.
- Litigation and Patent Challenges: No known current litigations against this specific patent, but generic challenges on utility and inventive step are common in this space.
Comparison with Other Key Patents
Comparative Table of Claims & Scope
| Patent/Claim Type |
Patent 8,420,592 |
Gilead's Remdesivir (US 8,778,892) |
Novartis' LDK378 (US 8,813,235) |
| Core chemical structure |
Pyrido[3,4-d]pyrimidine derivatives |
Nucleoside analogues |
Anilinoquinazoline derivatives |
| Target kinase |
Multiple (VEGFR, FLT3, PDGFR) |
Viral polymerase enzyme |
ALK kinase |
| Claims of therapeutic method |
Yes |
No |
No |
| Patent family breadth (number of claims) |
Broad, >20 claims |
Narrow, 10 claims |
Moderate, ~15 claims |
Consequence: The 8,420,592 has a broad chemical and method claim scope, positioning it as a foundational patent in the kinase inhibitor class, though overlapping with narrower therapy-specific patents.
Implications for Patent Strategies and Freedom to Operate
Strengths of the Patent
- Broad chemical genus claims with multiple substitution variants.
- Claims covering synthesis methods and therapeutic applications.
- Family extensions increase territorial protections.
Potential Challenges
- Art-based invalidation risks due to overlapping or similar chemical structures claimed elsewhere.
- Evolving patent landscapes in kinase inhibitors may lead to patent thickets, complicating freedom to operate.
- The need for careful prosecution to defend against obviousness or inventiveness rejections.
Opportunities for Innovators
- Designing compounds outside the claimed chemical scope.
- Developing alternative synthesis routes not covered by the patent claims.
- Targeting different kinase pathways, avoiding potential infringement.
Conclusion: Key Takeaways and Business Implications
| Insight |
Action Point |
| The patent covers a broad class of kinase inhibitors targeting multiple kinases |
Develop compounds outside the claimed chemical space |
| The claims' breadth provides strong protection but overlaps with competitors |
Conduct detailed freedom-to-operate analyses and monitor patent filings in kinase space |
| Strategic patent family extensions enhance territorial coverage |
Consider filing continuations or divisions to expand rights |
| The competitive landscape is dense, with overlapping patents |
Pursue innovation in unrelated chemical classes or mechanisms |
| The patent’s method claims bolster its defensibility in litigation |
Leverage method-specific claims for strategic licensing or defense |
Frequently Asked Questions (FAQs)
Q1: How broad are the claims of U.S. Patent 8,420,592?
A1: The patent's claims cover a wide chemical genus of pyrido[3,4-d]pyrimidine derivatives with multiple substituents, including various stereochemistries, and methods of therapeutic use, providing extensive protection in the kinase inhibitor space.
Q2: How does this patent compare to similar patents in kinase inhibitor technology?
A2: It boasts broader chemical and therapeutic claims than some contemporaneous patents, positioning it as a potentially foundational patent. However, overlapping claims necessitate detailed assessments for freedom to operate.
Q3: What is the patent landscape surrounding this patent?
A3: It is part of a network of patents filed by Eli Lilly and other pharmaceutical companies, targeting related kinase inhibitors and therapy methods. Over 50 related patents across multiple jurisdictions exist, with intense competition among major biotech firms.
Q4: Can this patent be challenged or designed around?
A4: Yes; designing compounds outside the specified chemical scope, utilizing alternative kinase targets, or developing different synthesis methods can potentially avoid infringement or invalidation.
Q5: What strategic considerations should patent owners or competitors derive from this patent?
A5: Owners should strengthen their patent portfolios to prevent infringement and consider licensing. Competitors should analyze and design around the claims, focusing on non-overlapping chemical or therapeutic spaces to avoid infringement or invalidation risks.
References
[1] United States Patent No. 8,420,592, issued April 16, 2013.
[2] WIPO Patent Application WO 2011/050918.
[3] US Patent No. 8,858,877.
[4] European Patent No. 2,560,447.
[5] Patent landscape reports from Patentscope and Espacenet databases.
[6] industry publications on kinase inhibitors and cancer therapeutics (2020-2022).
In conclusion, U.S. Patent 8,420,592 provides a robust legal framework protecting a significant chemical space of kinase inhibitors, crucial for Eli Lilly’s oncology portfolio. Its broad claims offer strong protections but also face intense competitive and legal scrutiny within a highly active patent landscape. Developers and strategic patent managers should conduct detailed analyses to navigate this terrain optimally.
More… ↓
⤷ Start Trial
|
